LARIMAR THERAPEUTICS, INC. Operating Lease Liability
LARIMAR THERAPEUTICS, INC. (LRMR) had Operating Lease Liability of $4.96 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-04
- 2026-06-30: Operating Lease, Liability $4.96M.
- 2026-03-31: Operating Lease, Liability $3.78M.
- 2025-12-31: Operating Lease, Liability $4.07M.
- 2025-09-30: Operating Lease, Liability $4.35M.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-06-30 | $4.96M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $3.78M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $4.07M 10-K · filed 2026-03-19 |
| 2025-09-30 | $4.35M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $4.61M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $4.87M 10-Q · filed 2025-04-30 |
| 2024-12-31 | $5.12M 10-K · filed 2025-03-24 |
| 2024-09-30 | $5.36M 10-Q · filed 2024-10-30 |
| 2024-06-30 | $5.59M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $5.34M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $5.55M 10-K · filed 2024-03-14 |
| 2023-09-30 | $5.39M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $5.08M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $5.25M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $5.41M 10-K · filed 2023-03-14 |
| 2022-09-30 | $5.57M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $5.71M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $5.86M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $6.00M 10-K · filed 2022-03-25 |
| 2021-09-30 | $6.14M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $6.27M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $6.39M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $6.52M 10-K · filed 2021-03-04 |
| 2020-09-30 | $6.66M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $6.86M 10-Q · filed 2020-08-14 |
| 2020-03-31 | $6.76M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $6.84M 10-K · filed 2020-03-05 |
| 2019-09-30 | $6.91M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $7.05M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $899.00K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |